🔥 Hot Today in Peptide Research

🔥🔥

Eight days left on the HHS peptide docket. Late comments are not accepted

Photo: Image: BioLabs Research

The Federal Register notice for HHS's enforcement-discretion policy on 503A compounding with certain peptide bulk drug substances (FR Doc. 2026-22192, published 30 October 2026) says written comments may be filed until two weeks after publication on docket HHS-OASH-2026-0496. That window closes on 13 November 2026. A regulations.gov refresh on the evening of 5 November 2026 still showed 12 posted comments, the docket still open for comment, and late comments not allowed. The same notice states the policy creates no rights for any person and is not binding on HHS or the public. It is a notice of availability, not an FDA approval of any compounded product. Our FDA Peptide Compounding Policy Tracker follows each step.

Read the Full Update

For research-community awareness only. Not legal advice.

🔥🔥

A biofilm-derived peptide that glues wet surfaces under water

Photo: Image: BioLabs Research

Science Advances reports a peptide derived from bacterial biofilms that adsorbs onto various surfaces and can glue wet surfaces under water. The authors characterised adsorption and adhesion with confocal microscopy, molecular dynamics simulations, atomic force microscopy, lap shear tests and spectroscopy, and also showed the peptide can coaggregate with microspheres as a flocculant. The work proposes bacterial biofilms as a design source for underwater adhesives, alongside the better-known marine-animal models. These are materials-science results only.

Read the Full Update

🔥🔥

Eight AI peptide sequencing models, one shared blind spot: missing fragment ions

Photo: Image: BioLabs Research

A benchmark published in Nature Methods on 3 November 2026 compared eight deep-learning models that read peptide sequences straight from mass spectra, without a sequence database, on three public proteomics datasets. Performance varied between models, but many correct identifications overlapped. Post-processing steps such as iterative refinement, rescoring and reranking gave no or only modest gains. Most errors were the same across models and traced to limited fragment-ion coverage, the gaps in a spectrum where no fragment shows which residue comes next; the authors saw the same limit in database searches with large search spaces. Look-alike residue pairs of equal mass, such as leucine and isoleucine, remain hard to tell apart. These are analytical method results only.

Read the Full Update

🔥🔥

FDA reviewers said no to all six peptides. HHS cites lab certificates that are not public yet

Photo: Image: BioLabs Research

Appendix B of the HHS 503A peptide policy, published in the Federal Register on 30 October 2026 (FR Doc. 2026-22192), says the FDA's drug center, CDER, recommended against listing each of the six peptides. HHS gives three reasons for going ahead: historical use it calls documented and quantified, lot-specific certificates of analysis from FDA-registered facilities that it says were not before CDER, and a view that CDER's safety concerns were inferential or mechanistic rather than observed harm. BioXconomy reported on 4 November 2026 that none of the evidence the HHS document refers to had been provided as of publication. Comments on docket HHS-OASH-2026-0496 close at 11:59 PM Eastern on 13 November 2026. The policy is not an FDA approval.

Read the Full Update

For research-community awareness only. Not legal advice.

🔥🔥

A simple splice in water joined short peptoid chains, a step toward much longer peptoids

Photo: Image: BioLabs Research

Berkeley Lab's Molecular Foundry reported on 2 November 2026 that a team working with New York University joined two short peptoid chains head to tail using native chemical ligation, a splicing reaction that runs in water and leaves no change in the backbone at the seam. Peptoids are peptide-like chains whose side chains sit on the nitrogen instead of the carbon. The building blocks, 14 to 20 building blocks (residues) long, were made on the Foundry's automated synthesizers. When an unexpected extra mass appeared, the team traced it to a side reaction at the first residue of the chain, seen only when a particular side chain sits in that position. The joined chains still assembled into nanosheets, as the shorter versions do. The work was published in Biochemistry, and a team member says peptoids 100 residues long now look within reach. These are lab chemistry results only.

Read the Full Update

🔥🔥

How long does the HHS peptide policy last? Its own text says it can change, or end

Photo: Image: BioLabs Research

The Department of Health and Human Services published its draft 503A peptide enforcement discretion policy in the Federal Register on 30 October 2026 (FR Doc. 2026-22192). The policy text says it applies only until each of the six peptide substances in its Appendix A is addressed in a final rule, as included or not included on the 503A bulks list. HHS says it may revisit the policy, in whole or in part, if a safety signal or product quality issue arises, and the notice says the policy is not binding on HHS or the public and creates no rights. The notice also tells readers to check the HHS website for the most current version. Comments on docket HHS-OASH-2026-0496 close at 11:59 PM Eastern on 13 November 2026; regulations.gov still showed 0 posted comments on 3 November. The policy is not an FDA approval.

Read the Full Update

For research-community awareness only. Not legal advice.

🔥🔥

A peptide from a plant's stress protein fought fungi and crossed a lab blood–brain barrier model

Photo: Image: BioLabs Research

ACS Omega published a study on 31 October 2026 on ERD-A, a lysine-rich peptide taken from a dehydrin, a stress-response protein of the lab plant Arabidopsis thaliana, plus rationally designed sequence variants. In lab tests the parent peptide showed moderate activity against the yeasts Candida albicans and Cryptococcus neoformans; variants with more positive charge or added tryptophan reached 4-fold lower minimum inhibitory concentrations against C. neoformans, while Candidozyma auris responded poorly to all versions. A labelled form associated with about 98 to 99% of C. albicans cells after 16 hours. In an in vitro blood–brain barrier model of cocultured human brain endothelial cells and pericytes, all ERD-A peptides passed through more readily than the reference peptide opiorphin. These are cell-model results only; no animal or human testing is reported.

Read the Full Update

🔥🔥

Four days in, the HHS peptide policy docket still shows zero public comments. Here is why that number can mislead

Photo: Image: BioLabs Research

Regulations.gov showed 0 posted comments on docket HHS-OASH-2026-0496 when we checked on 2 November 2026, four days after HHS published its draft 503A peptide enforcement discretion policy (FR Doc. 2026-22192) on 30 October. Regulations.gov says an agency must process each comment before it appears online, which can take days or weeks, so zero posted does not mean zero received. The docket is listed as nonrulemaking, the comment period ends at 11:59 PM Eastern on 13 November 2026, and late comments are not accepted. HHS says public comments may provide additional evidence that FDA can consider in rulemaking. The policy is interim and non-binding, and it is not an FDA approval.

Read the Full Update

For research-community awareness only. Not legal advice.

🔥🔥

A shortened scorpion-venom peptide stopped all 12 bacterial strains in lab tests; a half-length version stopped none

Photo: Image: BioLabs Research

Nature Africa reported on 29 October 2026 on University of Pretoria work that screened 116 antimicrobial peptides reported from African wildlife and kept 46 shorter candidates. A 16-amino-acid fragment of a southern African scorpion's venom peptide inhibited all 12 bacterial strains tested and showed little toxicity to mammalian cell lines, while an 8-amino-acid version showed no detectable activity. In wax-moth larvae infected with multidrug-resistant Acinetobacter baumannii, 87% of treated larvae survived, against 83% with the comparison antibiotic polymyxin B. The peptide kept activity in serum but was broken down by the enzyme trypsin. The larva results come from a preprint, and these are early findings only; stability, mammalian models and safety remain untested.

Read the Full Update

🔥🔥

Three things the new HHS peptide policy does not cover: blends, unregistered API makers and skipped adverse-event reports

Photo: Image: BioLabs Research

The HHS draft enforcement discretion policy for 503A compounding with six peptide bulk drug substances (FR Doc. 2026-22192, published 30 October 2026) applies only when all ten of its conditions are met. Under condition 7, a compounded product may contain only one active ingredient from Appendix A, so combining two or more falls outside it; HHS says this makes adverse events easier to attribute. Under conditions 3 and 4, the original manufacturer of the bulk substance, not a repacker or distributor, must be FDA-registered under section 510 and CGMP-compliant, with its facility address on the COA. Under condition 5, serious adverse events and quality issues go to FDA's MedWatch and the States. LumaLex Law noted on 29 October that missing any of these could put a compounder outside the policy. It is interim, non-binding and not an FDA approval; comments close 13 November 2026.

Read the Full Update

For research-community awareness only. Not legal advice.

🔥🔥

Two lab peptides flip a heart-cell calcium switch in opposite directions in mice

Photo: Image: BioLabs Research

Nature Cardiovascular Research published a study on 27 October 2026 from Albert Einstein College of Medicine, Thomas Jefferson University, Emory University and the University of Manitoba on mitofusins, proteins on the mitochondrial surface. The team used two cell-permeable peptides that change mitofusin shape in opposite ways. The activator brought the endoplasmic/sarcoplasmic reticulum and mitochondria closer, increased calcium transfer and enlarged infarct size in mice; this depended on mitofusin 2, not mitofusin 1, and on the mitochondrial calcium uniporter. The inhibitor reduced calcium transfer and infarct size in mice, even when given only after reperfusion began. The effects were independent of mitochondrial fusion. These are preclinical results only.

Read the Full Update

🔥🔥

HHS peptide policy: why a purity number alone no longer counts as a full COA

Photo: Image: BioLabs Research

The HHS draft enforcement discretion policy for 503A compounding with six peptide bulk drug substances (FR Doc. 2026-22192, published 30 October 2026) lists in Appendix B what a certificate of analysis must contain; Drug Topics noted on 29 October that a purity percentage alone would be insufficient. The list includes the original manufacturer's name, FDA Establishment Identifier and address, batch number, synthesis, release and expiry dates, identity confirmed by at least two independent orthogonal methods, impurity, residual solvent, elemental impurity and endotoxin results, and a dated signature from the quality unit. A registered distributor or repacker does not replace registration of the original manufacturer. The policy covers compounding for patients only, is interim, non-binding and not an FDA approval. Comments close on 13 November 2026.

Read the Full Update

For research-community awareness only. Not legal advice.

🔥🔥

A lipid-tailed ring peptide jams the COVID spike and improved survival in mice

Photo: Image: BioLabs Research

Nature Communications published a study on 28 October 2026 from Shionogi and Hokkaido University describing S-880008, a lipid-modified macrocyclic peptide found through mRNA display screening and then structurally optimised as a SARS-CoV-2 fusion inhibitor. In lab tests it was active against diverse variants, including Omicron lineages. Cryo-electron microscopy showed an unusual dual-binding mechanism: the ring portion anchors a conserved, normally hidden site between the receptor-binding domain and subdomain 1, while the lipid chain reaches into the neighbouring protomer. Together they hold the spike in an all-up conformation, stopping the protomers from separating and blocking fusion. In a mouse infection model it reduced viral titers and improved survival. These are preclinical results only.

🔥🔥

Peptide Policy: 14 Days to Speak. Then What?

Photo: Image: BioLabs Research

Regulations.gov opened docket HHS-OASH-2026-0496 on 30 October 2026 for the HHS draft enforcement discretion policy on 503A compounding with six peptide bulk drug substances, published the same day in the Federal Register (FR Doc. 2026-22192, 91 FR 68526). The docket lists a comment deadline of 11:59 p.m. Eastern on 13 November 2026 and does not accept late comments. HHS files it as a nonrulemaking docket: comments go into a record FDA may consider in future 503A bulks list rulemaking, and they are not a vote. No public comments were posted when we checked on the evening of 30 October. The policy stays interim, non-binding and is not an FDA approval.

Read the Full Update

For research-community awareness only. Not legal advice.

🔥🔥

AI designed 46 lipopeptides and 44 worked against bacteria

Photo: Image: BioLabs Research

Nature Communications published a study on 17 October 2026 from Shanghai Jiao Tong University describing a deep-learning model that treats the N-terminal fatty-acid chain as a prompt when predicting the antimicrobial activity of lipopeptides. The team mined 2,657 RiPP-derived core peptide sequences from 96,911 bacterial genomes, virtually attached seven fatty-acid chains (C6 to C18) and screened 6,197 candidates down to 289. Of 46 synthesized at random, 44 showed antimicrobial activity, a 95.7% hit rate. The lead compound, LP630, was active against Gram-positive, Gram-negative and mycobacterial strains in the lab and in mouse wound-infection models. These are preclinical results only.

🔥🔥

New Peptide Policy: Who Cheered and Who Pushed Back

Photo: Image: BioLabs Research

BioSpace reported on 29 October 2026 that reactions to the HHS draft enforcement discretion policy for 503A compounding with six peptide bulk drug substances split along the same lines as comments to the FDA's Pharmacy Compounding Advisory Committee. The Alliance for Pharmacy Compounding called it "an important step for patients" and the American Academy of Peptide Medicine called it "a vital step toward eliminating the unsafe gray and black markets." The Partnership for Safe Medicines said it "leaves Americans in a gray area", and PhRMA said HHS was telling the FDA to "ignore the law." The six match the advisory committee's July recommendation; the committee voted against a seventh. The policy is interim, non-binding and not an FDA approval. Comments open for two weeks after Federal Register publication, set for 30 October.

For research-community awareness only. Not legal advice.

BioLabs Research has no affiliation with, and no endorsement from, any person named. Source: BioSpace

🔥🔥

HHS Names 6 Peptides It Won't Act Against. The Fine Print

Photo: Image: BioLabs Research

HHS filed a notice for Federal Register public inspection on 28 October 2026 (publication set for 30 October), announcing a draft enforcement discretion policy for 503A compounding with certain peptide bulk drug substances. HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding with the six peptide bulk drug substances in its Appendix A, but only if strict conditions are met. Conditions include a patient-specific prescription, a registered original manufacturer, a certificate of analysis covering identity, purity, potency, impurities and endotoxins, single-ingredient products and adverse-event reporting. HHS says the policy aims to discourage research-use-only peptides from foreign suppliers. Comments run two weeks after publication. The policy is not binding and is not an FDA approval.

Read the Full Update

For research-community awareness only. Not legal advice.

🔥

Peptide API maker Hybio reports a 512% profit rise and plans to double its Wuhan peptide capacity

Photo: Image: BioLabs Research

Shenzhen Hybio Pharmaceutical, a Chinese peptide API maker, reported nine-month 2026 revenue of RMB 1.24 billion, up 81.9%, and attributable net profit of RMB 436.6 million, up 512%, attributing the growth mainly to higher API sales, Peptide & Protein News reported on 26 October 2026. The same board meeting approved spending of up to RMB 380 million on a Wuhan expansion that the company says would add 10,000 kg a year of peptide capacity to the 10,000 kg already there, citing short upstream supply for incretin-class APIs. Environmental approval and a shareholder vote are still pending, and no start-up date was given. The planned equipment includes industrial preparative HPLC systems, the purification step behind the purity results a lot-level certificate of analysis reports.

🔥

DuPont adds a silica chromatography media as peptide purification capacity comes under pressure

Photo: Image: BioLabs Research

DuPont said on 22 October 2026 that it has launched AmberChrom SIL, a reverse-phase silica gel in C8 and C18 chemistries for purifying peptides at manufacturing scale, from crude purification through final high-purity polishing. The company said rising peptide demand is pushing manufacturers to build purification processes that reach demanding purity targets without giving up yield, and that the new media can be combined with its polymeric resins in a single workflow. Its performance claims come from company application studies, not independent data. Reverse-phase chromatography is the step that strips synthesis by-products from crude peptide, and the purity and impurity profile it delivers are the results a lot-level certificate of analysis reports.

🔥🔥

FDA peptide compounding plan would reportedly require purity and identity certification and adverse-event reporting

Photo: BioLabs Research

Bloomberg News reported on 22 October 2026, citing people familiar with the matter, that the FDA peptide compounding notice under White House review would let compounding pharmacies make certain peptides without FDA enforcement only if they certify the substances' purity and identity and report serious adverse events. FDA and HHS have not confirmed this. The notice (RIN 0910-ZD94) was still pending at reginfo.gov on 26 October, and its text, covered substances and conditions are unpublished. Purity and identity are the two core results on a lot-level certificate of analysis. A pending review is not a published policy or an FDA approval.

Read the Full Update

For research-community awareness only. Not legal advice.

🔥🔥

Citizen petition asks FDA not to allow compounding of the seven peptides reviewed by its July advisory committee

Photo: BioLabs Research

The Partnership for Safe Medicines, a drug-safety advocacy group, has filed a citizen petition (21 CFR 10.30, marked submitted via Regulations.gov on 23 October 2026) asking FDA not to allow compounding with any of the seven peptide bulk drug substances its Pharmacy Compounding Advisory Committee reviewed in July, whether by rule, by a Category 1 interim-policy listing or by enforcement discretion. FDA reviewers had recommended against all seven; the committee voted for six. The group alleges the committee was improperly constituted, which FDA has not ruled on. A petition is a request, not an FDA decision; the related White House-reviewed notice remains unpublished.

Read the Full Update

For research-community awareness only. Not legal advice.

🔥🔥

FDA peptide compounding notice: White House review log now lists six outside meetings, text still unpublished

Photo: BioLabs Research

The White House Office of Information and Regulatory Affairs (OIRA) still listed the FDA notice 'Interim Access Policy for Compounding Using Certain Peptides' (RIN 0910-ZD94) as pending review on 24 October 2026, ten days after receiving it. OIRA's public log now shows six meetings with outside parties between 21 and 28 October, requested by a peptide-medicine academy, a telehealth company, a compounding trade group, a consumer-advocacy group and two consultancies for their clients. The records show who asked to meet, not what was said; the notice text, covered substances and any conditions remain unpublished, and a pending review is not a published policy or an FDA approval.

Read the Full Update

For research-community awareness only. Not legal advice.